An Open-Label, Non-Randomized, Single-Center Study to Preliminary Evaluation of Safety and Efficacy of Patients Who Participant in [14C] AC0010 Trail and Subsequent Receiving AC0010 Treatment

Trial Profile

An Open-Label, Non-Randomized, Single-Center Study to Preliminary Evaluation of Safety and Efficacy of Patients Who Participant in [14C] AC0010 Trail and Subsequent Receiving AC0010 Treatment

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2018

At a glance

  • Drugs Abivertinib-maleate (Primary)
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Hangzhou ACEA Pharmaceutical Research
  • Most Recent Events

    • 28 Jun 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 28 Jun 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
    • 29 Sep 2017 Planned number of patients changed from 6 to 7.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top